Novel combined GPIHBP1 mutations in a patient with hypertriglyceridemia associated with CAD

Journal of Atherosclerosis and Thrombosis

Volumn 20, Issue 10, 2013, Pages 777-784

  Yamamoto, Hiroyasu ^a   Onishi, Misa ^a   Miyamoto, Naoko ^a   Oki, Ryosuke ^b   Ueda, Hiroyasu ^b   Ishigami, Masato ^a   Hiraoka, Hisatoyo ^b   Matsuzawa, Yuji ^b   Kihara, Shinji ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SUMITOMO HOSPITAL   (Japan)

Author keywords

Atherosclerosis; GPIHBP1; Hypertriglyceridemia; LPL

Indexed keywords

CHOLESTEROL; TRIACYLGLYCEROL;

ACUTE PANCREATITIS; ADULT; ARTICLE; CASE REPORT; CELL STRAIN HEK293; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DNA SEQUENCE; FEMALE; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED HIGH DENSITY LIPOPROTEIN BINDING PROTEIN 1 GENE; HUMAN; HUMAN CELL; HYPERTRIGLYCERIDEMIA; LIPID ANALYSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

CORONARY ARTERY DISEASE; FEMALE; HEK293 CELLS; HUMANS; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN LIPASE; MIDDLE AGED; MUTATION; RECEPTORS, LIPOPROTEIN;

EID: 84886711197     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.18861     Document Type: Article

References (33)

1. National Cholesterol Education Program (NCEP) Expert Panel on Detection E, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation, 2002; 106: 3143-3421.
2. Goldberg IJ: Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res, 1996; 37: 693-707.
3. Fojo SS, Stalenhoef AF, Marr K, Gregg RE, Ross RS, Brewer HB Jr: A deletion mutation in the ApoC-IIgene (ApoC-IINijmegen) of a patient with a deficiency of apolipoprotein C-II. J Biol Chem, 1988; 263: 17913-17916.
4. Calandra S, Priore Oliva C, Tarugi P, Bertolini S: APOA5 and triglyceride metabolism, lesson from human APOA5 deficiency. Curr Opin Lipidol, 2006; 17: 122-127.
5. Peterfy M, Ben-Zeev O, Mao HZ, Weissglas-Volkov D, Aouizerat BE, Pullinger CR, Frost PH, Kane JP, Malloy MJ, Reue K, Pajukanta P, Doolittle MH: Mutations in LMF1 cause combined lipase deficiency and severe hypertriglyceridemia. Nat Genet, 2007; 39: 1483-1487.
6. Beigneux AP, Davies BS, Gin P, Weinstein MM, Farber E, Qiao X, Peale F, Bunting S, Walzem RL, Wong JS, Blaner WS, Ding ZM, Melford K, Wongsiriroj N, Shu X, de Sauvage F, Ryan RO, Fong LG, Bensadoun A, Young SG: Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab, 2007; 5: 279-291.
7. Davies BS, Beigneux AP, Barnes RH, 2nd, Tu Y, Gin P, Weinstein MM, Nobumori C, Nyren R, Goldberg I, Olivecrona G, Bensadoun A, Young SG, Fong LG: GPIHBP1 is responsible for the entry of lipoprotein lipase into capillaries. Cell Metab, 2010; 12: 42-52.
8. Ikeda Y, Takagi A, Ohkaru Y, Nogi K, Iwanaga T, Kurooka S, Yamamoto A: A sandwich-enzyme immunoassay for the quantification of lipoprotein lipase and hepatic triglyceride lipase in human postheparin plasma using monoclonal antibodies to the corresponding enzymes. J Lipid Res, 1990; 31: 1911-1924.
9. Nozaki S, Kubo M, Matsuzawa Y, Tarui S: Sensitive nonradioisotopic method for measuring lipoprotein lipase and hepatic triglyceride lipase in post-heparin plasma. Clin Chem, 1984; 30: 748-751.
10. Nordestgaard BG, Tybjaerg-Hansen A: IDL, VLDL, chylomicrons and atherosclerosis. Eur J Epidemiol, 1992; 8 Suppl 1: 92-98.
11. Ebara T, Okubo M, Horinishi A, Adachi M, Murase T, Hirano T: No evidence of accelerated atherosclerosis in a 66-yr-old chylomicronemia patient homozygous for the nonsense mutation (Tyr61-->stop) in the lipoprotein lipase gene. Atherosclerosis, 2001; 159: 375-379.
12. Kawashiri MA, Higashikata T, Mizuno M, Takata M, Katsuda S, Miwa K, Nozue T, Nohara A, Inazu A, Kobayashi J, Koizumi J, Mabuchi H: Long-term course of lipoprotein lipase (LPL) deficiency due to homozygous LPL (Arita) in a patient with recurrent pancreatitis, retained glucose tolerance, and atherosclerosis. J Clin Endocrinol Metab, 2005; 90: 6541-6544.
13. Ebara T, Endo Y, Yoshiike S, Tsuji M, Taguchi S, Murase T, Okubo M: A 60-y-old chylomicronemia patient homozygous for missense mutation (G188E) in the lipoprotein lipase gene showed no accelerated atherosclerosis. Clin Chim Acta, 2007; 386: 100-104.
14. Benlian P, De Gennes JL, Foubert L, Zhang H, Gagne SE, Hayden M: Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. N Engl J Med, 1996; 335: 848-854.
15. Saika Y, Sakai N, Takahashi M, Maruyama T, Kihara S, Ouchi N, Ishigami M, Hiraoka H, Nakamura T, Yamashita S, Matsuzawa Y: Novel LPL mutation (L303F) found in a patient associated with coronary artery disease and severe systemic atherosclerosis. Eur J Clin Invest, 2003; 33: 216-222.
16. Yagyu H, Ishibashi S, Chen Z, Osuga J, Okazaki M, Perrey S, Kitamine T, Shimada M, Ohashi K, Harada K, Shionoiri F, Yahagi N, Gotoda T, Yazaki Y, Yamada N: Overexpressed lipoprotein lipase protects against atherosclerosis in apolipoprotein E knockout mice. J Lipid Res, 1999; 40: 1677-1685.
17. Semenkovich CF, Coleman T, Daugherty A: Effects of heterozygous lipoprotein lipase deficiency on diet-induced atherosclerosis in mice. J Lipid Res, 1998; 39: 1141-1151.
18. Clee SM, Bissada N, Miao F, Miao L, Marais AD, Henderson HE, Steures P, McManus J, McManus B, LeBoeuf RC, Kastelein JJ, Hayden MR: Plasma and vessel wall lipoprotein lipase have different roles in atherosclerosis. J Lipid Res, 2000; 41: 521-531.
19. Zhang X, Qi R, Xian X, Yang F, Blackstein M, Deng X, Fan J, Ross C, Karasinska J, Hayden MR, Liu G: Spontaneous atherosclerosis in aged lipoprotein lipase-deficient mice with severe hypertriglyceridemia on a normal chow diet. Circ Res, 2008; 102: 250-256.
20. Koike T, Liang J, Wang X, Ichikawa T, Shiomi M, Sun H, Watanabe T, Liu G, Fan J: Enhanced aortic atherosclerosis in transgenic Watanabe heritable hyperlipidemic rabbits expressing lipoprotein lipase. Cardiovasc Res, 2005; 65: 524-534.
21. Xu N, Ohlin AK, Nilsson A: Chylomicron-induced prothrombin activation and platelet aggregation. Arterioscler Thromb, 1994; 14: 1014-1020.
22. Zhao T, Guo J, Li H, Huang W, Xian X, Ross CJ, Hayden MR, Wen Z, Liu G: Hemorheological abnormalities in lipoprotein lipase deficient mice with severe hypertriglyceridemia. Biochem Biophys Res Commun, 2006; 341: 1066-1071.
23. Babaev VR, Fazio S, Gleaves LA, Carter KJ, Semenkovich CF, Linton MF: Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in vivo. J Clin Invest, 1999; 103: 1697-1705.
24. Serri O, Li L, Maingrette F, Jaffry N, Renier G: Enhanced lipoprotein lipase secretion and foam cell formation by macrophages of patients with growth hormone deficiency: possible contribution to increased risk of atherogenesis? J Clin Endocrinol Metab, 2004; 89: 979-985.
25. Weinstein MM, Yin L, Tu Y, Wang X, Wu X, Castellani LW, Walzem RL, Lusis AJ, Fong LG, Beigneux AP, Young SG: Chylomicronemia elicits atherosclerosis in mice--brief report. Arterioscler Thromb Vasc Biol, 2010; 30: 20-23.
26. Ioka RX, Kang MJ, Kamiyama S, Kim DH, Magoori K, Kamataki A, Ito Y, Takei YA, Sasaki M, Suzuki T, Sasano H, Takahashi S, Sakai J, Fujino T, Yamamoto TT: Expression cloning and characterization of a novel glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein, GPI-HBP1. J Biol Chem, 2003; 278: 7344-7349.
27. Surendran RP, Visser ME, Heemelaar S, Wang J, Peter J, Defesche JC, Kuivenhoven JA, Hosseini M, Peterfy M, Kastelein JJ, Johansen CT, Hegele RA, Stroes ES, Dallinga-Thie GM: Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia. J Intern Med, 2012; 272: 185-196.
28. Rios JJ, Shastry S, Jasso J, Hauser N, Garg A, Bensadoun A, Cohen JC, Hobbs HH: Deletion of GPIHBP1 causing severe chylomicronemia. J Inherit Metab Dis, 2012; 35: 531-540.
29. Coca-Prieto I, Kroupa O, Gonzalez-Santos P, Magne J, Olivecrona G, Ehrenborg E, Valdivielso P: Childhoodonset chylomicronaemia with reduced plasma lipoprotein lipase activity and mass: identification of a novel GPIHBP1 mutation. J Intern Med, 2011; 270: 224-228.
30. Charriere S, Peretti N, Bernard S, Di Filippo M, Sassolas A, Merlin M, Delay M, Debard C, Lefai E, Lachaux A, Moulin P, Marcais C: GPIHBP1 C89F neomutation and hydrophobic C-terminal domain G175R mutation in two pedigrees with severe hyperchylomicronemia. J Clin Endocrinol Metab, 2011; 96: E1675-E1679.
31. Olivecrona G, Ehrenborg E, Semb H, Makoveichuk E, Lindberg A, Hayden MR, Gin P, Davies BS, Weinstein MM, Fong LG, Beigneux AP, Young, SG, Olivecrona T, Hernell O: Mutation of conserved cysteines in the Ly6 domain of GPIHBP1 in familial chylomicronemia. J Lipid Res, 2010; 51: 1535-1545.
32. Beigneux AP, Franssen R, Bensadoun A, Gin P, Melford K, Peter J, Walzem RL, Weinstein MM, Davies BS, Kuivenhoven JA, Kastelein JJ, Fong LG, Dallinga-Thie GM, Young SG: Chylomicronemia with a mutant GPIHBP1 (Q115P) that cannot bind lipoprotein lipase. Arterioscler Thromb Vasc Biol, 2009; 29: 956-962.
33. Wang J, Hegele RA: Homozygous missense mutation (G56R) in glycosylphosphatidylinositol-anchored highdensity lipoprotein-binding protein 1 (GPI-HBP1) in two siblings with fasting chylomicronemia (MIM 144650). Lipids Health Dis, 2007; 6: 23